Bioequivalence studies
Executive Summary
FDA's Division of Bioequivalence is requesting that companies submit potency data for both reference products and test products in all bio studies. According to the division, some firms only submit data on the potency of the test drug. When a product has too high or too low a blood level, the data can help determine whether a potency difference is causing the problem, the division said.